Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis

被引:22
作者
Liu, Ning-Bo [1 ]
Peng, Tao [1 ]
Pan, Chao [2 ]
Yao, Yu-Yu [2 ]
Shen, Bo [1 ]
Leng, Jing [1 ]
机构
[1] Nanjing Med Univ, Dept Pathol, Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Atherosclerosis Res Ctr, Nanjing 210029, Jiangsu, Peoples R China
关键词
Apoptosis; Akt; Celecoxib; Caspase; Cell proliferation; COX-2; HCC; PCNA;
D O I
10.3748/wjg.v11.i40.6281
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the cyclooxygenase-2 (COX-2) expression level in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and the molecular mechanism of COX-2 selective inhibitor celecoxib-induced cell growth inhibition and cell apoptosis. METHODS: Hepatoma cells were cultured and treated with celecoxib. Cell in situ hybridization (ISH) and immunocytochemistry were used to detect COX-2 mRNA and protein expression. Proliferating cell nuclear antigen and phosphorylated Akt were also detected by immunocytochemistry assay. Cell growth rates were assessed by 3-(4, 5-dimethylthiazol-2-yl-2, 5-diphenyltetrazolium (MTT) bromide colorimetric assay. Celecoxib-induced cell apoptosis was measured by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and flow cytometry (FCM). The phosphorylated Akt and activated fragments of caspase-9, caspase-3 were examined by Western blotting analysis. RESULTS: Increased COX-2 mRNA and protein expression were detected in all three hepatoma cell lines. Celecoxib could significantly inhibit cell growth and the inhibitory effect was in a dose-and time-dependent manner evidenced by MTT assays and morphological changes. The apoptotic index measured by TUNEL increased correspondingly with the increased concentration of celecoxib and the reaction time. With 50 mu mol/L celecoxib treatment for 24 h, the apoptotic index of HepG2, BEL-7402 and SMMC-7721 cells was 25.01 +/- 3.08%, 26.40 +/- 3.05%, and 30.60 +/- 2.89%, respectively. Western blotting analysis showed remarkable activation of caspase-9, caspase-3 and dephosphorylation of Akt (Thr(308)). Immunocytochemistry also showed the reduction of PCNA expression and phosphorylation Akt (Thr(308)) after treatment with celecoxib. CONCLUSION: COX-2 mRNA and protein overexpression in HepG2, Bel-7402 and SMMC-7721 cell lines correlate with the increased cell growth rate. Celecoxib can inhibit proliferation and induce apoptosis of hepatoma cell strains in a dose-and time-dependent manner. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.
引用
收藏
页码:6281 / 6287
页数:7
相关论文
共 49 条
  • [41] Mechanisms underlying aspirin-mediated growth inhibition and apoptosis induction of cyclooxygenase-2 negative colon cancer cell line SW480
    Lai, Ming-Yu
    Huang, Jie-An
    Liang, Zhi-Hai
    Jiang, Hai-Xing
    Tang, Guo-Du
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (26) : 4227 - 4233
  • [42] Knockdown of GCF2/LRRFIP1 by RNAi Causes Cell Growth Inhibition and Increased Apoptosis in Human Hepatoma HepG2 Cells
    Li, Jing-Ping
    Cao, Nai-Xia
    Jiang, Ri-Ting
    He, Shao-Jian
    Huang, Tian-Ming
    Wu, Bo
    Chen, De-Feng
    Ma, Ping
    Chen, Li
    Zhou, Su-Fang
    Xie, Xiao-Xun
    Luo, Guo-Rong
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (06) : 2753 - 2758
  • [43] Dolastatin 15, a mollusk linear peptide, and Celecoxib, a selective cyclooxygenase-2 inhibitor, prevent preneoplastic colonic lesions and induce apoptosis through inhibition of the regulatory transcription factor NF-κB and an inflammatory protein, iNOS
    Piplani, Honit
    Vaish, Vivek
    Sanyal, Sankar Nath
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2012, 21 (06) : 511 - 522
  • [44] Inhibition of angiogenic tubule formation and induction of apoptosis in human endothelial cells by the selective cyclooxygenase-2 inhibitor 5-bromo-2-(4-fluorophenyl)-3-(methylsulfonyl) thiophene (DuP-697)
    Churchman, Adrian
    Baydoun, Anwar R.
    Hoffman, Richard
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 573 (1-3) : 176 - 183
  • [45] The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: A phase II study with biological correlates
    Gasparini, G
    Meo, S
    Comella, G
    Stani, SC
    Mariani, L
    Gamucci, T
    Avallone, A
    Lo Vullo, S
    Mansueto, G
    Bonginelli, P
    Gattuso, D
    Gion, M
    CANCER JOURNAL, 2005, 11 (03) : 209 - 216
  • [46] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
    Gadgeel, Shirish M.
    Ruckdeschel, John C.
    Heath, Elisabeth I.
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Wozniak, Antoinette
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 299 - 305
  • [47] Inhibition of human rheumatoid arthritis synovial cell survival by hecogenin and tigogenin is associated with increased apoptosis, p38 mitogen-activated protein kinase activity and upregulation of cyclooxygenase-2
    Liagre, Bertrand
    Vergne-Salle, Pascale
    Leger, David Y.
    Beneytout, Jean-Louis
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2007, 20 (04) : 451 - 460
  • [48] Inhibition of Cyclooxygenase-2 (COX-2) Initiates Autophagy and Potentiates MPTP-Induced Autophagic Cell Death of Human Neuroblastoma Cells, SH-SY5Y: an Inside in the Pathology of Parkinson's Disease
    Niranjan, Rituraj
    Mishra, Kaushal Prasad
    Thakur, Ashwani Kumar
    MOLECULAR NEUROBIOLOGY, 2018, 55 (10) : 8038 - 8050
  • [49] Epidermal growth factor-induced cyclooxygenase-2 expression in oral squamous cell carcinoma cell lines is mediated through extracellular signal-regulated kinase 1/2 and p38 but is Src and nuclear factor-kappa B independent
    Husvik, Camilla
    Bryne, Magne
    Halstensen, Trond S.
    EUROPEAN JOURNAL OF ORAL SCIENCES, 2009, 117 (05) : 528 - 535